Sharekhan

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

What’s Your Call?

Collective community sentiment on Concord Drugs Ltd

Your Vote -

Buy

86.67%

Hold

0.00%

Sell

13.33%

86.67%

15 users have voted

No Records Found

Option Chain

Analyzes market sentiment, predicts Concord Drugs Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Concord Drugs - General Update

    16 Feb 2026, 3:11PM General Update
  • Concord Drugs - Financial Results For Quarter Ended 31St Dec,2025

    14 Feb 2026, 4:47PM Un-Audited Stand alone and Consolidated Results for Quarter Ended 31st Dec,2025.
  • Concord Drugs - Board Meeting Outcome for Out Come Of Board Meetings

    14 Feb 2026, 4:37PM Board of Directors approved financial results for 31 st December,2025
  • Concord Drugs - Reconstitution Of Committees

    14 Feb 2026, 4:35PM Reconstitution of Committees
  • Concord Drugs - Announcement under Regulation 30 (LODR)-Retirement

    14 Feb 2026, 4:30PM Announcement under Regulation 30 of LODR
  • Concord Drugs - Board Meeting Intimation for Quarterly Results

    2 Feb 2026, 5:00PM Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 ,inter alia, to consider and ap
  • Concord Drugs has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2025

    21 Jan 2026, 6:20PM As of December 2025, 54.39% is owned by Indian Promoters and 45.61% by Public. <p align=justify> Top three Promoters holding highest number of shares
  • Concord Drugs - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    20 Jan 2026, 1:17PM Certificate under Reg 74(5) of SEBI (DP) regulations
  • Concord Drugs Bags Purchase Orders Worth Rs 14.71 cr in December

    30 Dec 2025, 1:37PM Concord Drugs Ltd has received significant purchase orders from multiple domestic entities for the supply of pharmaceutical products during December 2
  • Concord Drugs - Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order

    30 Dec 2025, 11:31AM Company has received purchase orders from various entities for supply of it's products.

Key fundamentals

Evaluate the intrinsic value of Concord Drugs Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 48.9734 47.8258 46.5061 44.7948 39.7395
Liabilities 48.9734 47.8258 46.5061 44.7948 39.7395
Equity 10 10 9.3155 8.7437 8.7438
Gross Profit 3.7633 3.6772 4.3437 5.5924 3.2198
Net Profit 0.2957 0.4194 0.8922 1.5943 3.2817
Cash From Operating Activities 3.1631 1.9598 2.2448 0.7741 1.6157
NPM(%) 0.8 0.96 1.73 2.7 6.38
Revenue 36.9321 43.2607 51.3143 58.9564 51.357
Expenses 33.1688 39.5835 46.9706 53.3639 48.1372
ROE(%) 0.78 1.1 2.35 4.21 8.67

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Concord Drugs Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 708.70 -0.24 42.25 45.09 301.39 0.70
Lotus Eye Hospital and Institute Ltd 111.00 1.83 355.45 164.29 3.55 0.00
Bharat Immunological and Biologicals Corporation Ltd 17.92 1.53 0.00 341.12 -39.50 0.00
Astec Lifesciences Ltd 623.95 -0.13 0.00 154.93 -604.75 0.00

Company Info

Concord Drugs Limited (CDL) is incorporated as a Limited Company on 24th April 1995 with the Registrar of companies, Andhra Pradesh. The registered office of the Company is situated at Survey No. 249, Brahmanpally Village, Hayatnagar Mandal, R.R. District, Hyderabad-501511 Concord Drugs Limited was established in 1995 to manufacture and market innovative pharmaceutical products. Concord's three core product areas are generics, branded and specialty pharmaceuticals. The Company ranks among the top generics suppliers in India. Manufacturers of AMCRYLATE [ISO Amyl 2-Cyanoacrylate] a sterile tissue adhesive used in for sutureless surgeries first time in Asia in collaboration with Indian Institute of Chemical Technology [IICT], Hyderabad a premier CSIR Laboratory. The Technology Information, Forecasting and Assessment Council [TIFAC], New Delhi has helped the company to mass produce `AMCRYLATE' and bring it to Indian consumers. TIFAC was also associated in providing Techno-managerial guidance to the Company. The product is patented in India for Concord Drugs Limited. Further the Company has established Unit-II or Phase-II at Roorkee, Uttrakhand in 2005 for manufacturing of Tablets & Capsules.AMCRYLATE is non-pigmented, non-toxic, non-allergic, bacteriostatic and bio-static adhesive. It allows rapid wound closure with minimal scarring, reduces the risk of post surgical infection and trauma, besides being simple and safe to use.Also set-up a plant for Small Volume Parenterals in liquid ampoules/vials and powder Parenterals and also Tablets & Capsules with Betalactum & Non-Betalactum both sections. 2015 -Concord Drugs Ltd are listed and admitted to dealings on the Exchange in the list of 'DT' Group Securities.

Concord Drugs Limited (CDL) is incorporated as a Limited Company on 24th April 1995 with the Registrar of companies, Andhra Pradesh. The registered office of the Company is situated at Survey No. 249, Brahmanpally Village, Hayatnagar Mandal, R.R. District, Hyderabad-501511 Concord Drugs Limited was established in 1995 to manufacture and market innovative pharmaceutical products. Concord's three core product areas are generics, branded and specialty pharmaceuticals. The Company ranks among the top generics suppliers in India. Manufacturers of AMCRYLATE [ISO Amyl 2-Cyanoacrylate] a sterile tissue adhesive used in for sutureless surgeries first time in Asia in collaboration with Indian Institute of Chemical Technology [IICT], Hyderabad a premier CSIR Laboratory. The Technology Information, Forecasting and Assessment Council [TIFAC], New Delhi has helped the company to mass produce `AMCRYLATE' and bring it to Indian consumers. TIFAC was also associated in providing Techno-managerial guidance to the Company. The product is patented in India for Concord Drugs Limited. Further the Company has established Unit-II or Phase-II at Roorkee, Uttrakhand in 2005 for manufacturing of Tablets & Capsules.AMCRYLATE is non-pigmented, non-toxic, non-allergic, bacteriostatic and bio-static adhesive. It allows rapid wound closure with minimal scarring, reduces the risk of post surgical infection and trauma, besides being simple and safe to use.Also set-up a plant for Small Volume Parenterals in liquid ampoules/vials and powder Parenterals and also Tablets & Capsules with Betalactum & Non-Betalactum both sections. 2015 -Concord Drugs Ltd are listed and admitted to dealings on the Exchange in the list of 'DT' Group Securities.

Read More

Parent Organisation

Concord Drugs Ltd.

Founded

24/04/1995

Managing Director

Mr.S Nagi Reddy

NSE Symbol

FAQ

The current price of Concord Drugs Ltd is

The 52-week high for Concord Drugs Ltd is

The market capitalization of Concord Drugs Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Concord Drugs Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Concord Drugs Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Concord Drugs Ltd shares.

The CEO of Concord Drugs Ltd is Mr.S Nagi Reddy, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT